References
Hartmann O, Le Coroller AG, Blaise D, Michon J, Philip I, Norol F et al. Peripheral blood stem cells and bone marrow transplantation for solid tumors and lymphomas : hematologic recovery and costs. Ann Intern Med 1996; 126: 600–607.
Le Corroller AG, Moatti JP, Chabannon C, Faucher C, Fortanier C, Ladaique P et al. Optimization of peripheral blood stem cell collection by leukapheresis: a case of interaction between economic and clinical assessment of an innovation. Int J Technol Assessment Health Care 1999; 15: 161–172.
Gratwohl A, Passweg J, Baldomero H, Urbano-Ispizua A . Hematopoietic stem cell transplantation activity in Europe 1999. Bone Marrow Transplant 2001; 27: 899–916.
Weaver C, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961–3969.
Faucher C, Fortanier C, Viens P, Le Coroller AG, Chabannon C, Camerlo J et al. Clinical and economical comparison of lenograstim-primed blood cells (BC) and bone marrow (BM) allogeneic transplantation. Bone Marrow Transplant 1998; 21: S92-S98.
Pecora AL, Stiff P, LeMaistre CF, Bayer R, Bachier C, Goldberg SL et al. A phase II trial evaluating the safety and effectiveness of the AastromReplicell system for augmentation of low-dose blood stem cell transplantation. Bone Marrow Transplant 2001; 28: 295–303.
Ketterer N, Salles G, Raba M, Espinousse D, Sonnet A, Tremisi P et al. High CD34+ cell counts decrease hematologic toxicity of autologous peripheral blood cell transplantation. Blood 1998; 91: 3148–3155.
Schulman KA, Birch R, Zhen B, Pania Z, Weaver CH . Effect of CD34+ cell dose on ressource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support. J Clin Oncol 1999; 17: 1227–1233.
Acknowledgements
This work was supported in part by Institut Paoli-Calmettes. The authors thank Mr Christian Cailliot at Amgen France for his support during the conduct of this study.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chabannon, C., Le Corroller, AG., Viret, F. et al. Cost–effectiveness of repeated aphereses in poor mobilizers undergoing high-dose chemotherapy and autologous hematopoietic cell transplantation. Leukemia 17, 811–813 (2003). https://doi.org/10.1038/sj.leu.2402867
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402867
- Springer Nature Limited
This article is cited by
-
Danger-associated molecular pattern molecules take unexpectedly a central stage in Nlrp3 inflammasome–caspase-1-mediated trafficking of hematopoietic stem/progenitor cells
Leukemia (2021)
-
Plerixafor in poor mobilizers with non-Hodgkin’s lymphoma: a multi-center time-motion analysis
Bone Marrow Transplantation (2018)
-
Novel insight into stem cell mobilization-Plasma sphingosine-1-phosphate is a major chemoattractant that directs the egress of hematopoietic stem progenitor cells from the bone marrow and its level in peripheral blood increases during mobilization due to activation of complement cascade/membrane attack complex
Leukemia (2010)
-
Impaired mobilization of hematopoietic stem/progenitor cells in C5-deficient mice supports the pivotal involvement of innate immunity in this process and reveals novel promobilization effects of granulocytes
Leukemia (2009)
-
A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma
Bone Marrow Transplantation (2009)